ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

Inclusion Criteria:

• Is at least the local legal age of consent for clinical studies and at least aged 18years and less than 70 years

• Agree to use contraceptive measures consistent with local regulations

• Are diagnosed with ESRD and have been stable on chronic dialysis for at least 3months

• Are recipients of de novo or second-time, single kidney transplant from a deceaseddonor, either DCD (donation after cardiac/circulatory death) or DBD ( (donationafter brain death)

• Are ABO compatible with donor allograft, except for type A2 donor to type Brecipient kidneys

• Have a negative cross match

• Have received pretransplant vaccinations for: Neisseria meningitidis, Streptococcuspneumoniae, and Haemophilus influenzae, or are willing to receive the vaccinationsapproximately 3 to 4 months posttransplant

Exclusion Criteria:

• Any history of prothrombotic disorder or history of thrombosis or hypercoagulablestate, excluding vascular access clotting

• Any known history of complement deficiency

• Evidence of peritonitis in participants on peritoneal dialysis

• Received any solid organ, bone marrow, or hematopoietic stem cell transplant, withthe exception of prior first kidney transplant

• High risk within the study period for recurrence of underlying renal disease in theopinion of the investigator

• Clinically significant comorbidity, recent major surgery (within 3 months ofscreening), history of any treatment nonadherence, or intention to have surgeryduring the study other than kidney transplantation; or any other medical conditionthat, in the investigator's opinion, would confound the results of the study or putthe participant at undue risk

• Clinically significant active bacterial, viral, or fungal infection

• History of malignancy unless considered cured by adequate treatment, with noevidence of recurrence for 5 years or more before first study drug administration.Adequately treated participants with the following cancers can be included at anytime: Basal cell or squamous cell skin cancer; Carcinoma in situ of the cervix;Carcinoma in situ of the breast; Incidental histological finding of prostate cancer

• History of current alcohol, drug, or medication abuse as assessed by theinvestigator

• Pregnant or lactating state or intention to become pregnant during the study

The full list of criteria can be found in the protocol.